The authors sought to generate a synthetic extracellular volume fraction (ECV) from the relationship between hematocrit and longitudinal relaxation rate of blood.
I n health and disease, cardiac function is governed by an intricate interplay between myocardial cellular and interstitial components (1) .
Changes in the extracellular matrix (ECM) occur in adverse remodeling, e.g. diffuse fibrosis (2-4). Cardiac magnetic resonance (CMR) now permits measurement of this by using T1 mapping to quantify the extracellular volume fraction (ECV) (5, 6) . T1 mapping measures the longitudinal relaxation time, which is altered by myocardial fibrosis, edema, iron overload, and infiltrative diseases like amyloidosis (7, 8) . After administration of a gadolinium-based extracellular contrast agent, T1 is shortened. The ECV is derived from the ratio of changes in signal in myocardium and blood pre-and post-contrast and involves correction for the blood hematocrit. Early data suggests that ECV predicts mortality and major adverse cardiac events independently and as well as left ventricular ejection fraction excluding hypertrophic cardiomyopathy, amyloidosis, or congenital heart disease (9, 10) . Hematocrit (Hct) measurement is needed, which is cumbersome, introduces variability, and delays workflow, impeding adoption of the method (11) (12) (13) .
The longitudinal relaxivity (R1 ¼ 1/T1) of blood has been studied since the 1980s and was found to be in a linear relationship with blood Hct. It is determined by the water fractions of plasma and the erythrocyte cytoplasm, which undergo fast water exchange (7, (14) (15) (16) (17) (18) (19) (20) .
We hypothesize that this relationship could be used to estimate a synthetic Hct, permitting immediate synthetic ECV calculation without blood sampling. We formed a network of collaboration with existing key patient cohorts to investigate whether synthetic ECV: 1) was valid compared to conventional ECV; 2) correlated with the gold standard collagen volume fraction (CVF); 3) predicted outcome and 4) could be automated for inline point-of-care use.
METHODS
PATIENT POPULATIONS. Research was carried out at 2 centers ( Table 1) Proof-of-concept of synthetic ECV: cohorts 1 (derivation) and 2 (validation). A total of n ¼ 427 subjects gave written informed consent and were scanned between January 2012 and October 2014. They were then randomly split into derivation and validation subgroups ( Table S1) CMR ¼ cardiovascular magnetic resonance. T1 ANALYSIS AND ECV QUANTIFICATION. A region of interest was drawn in myocardium (in the septum on a short-axis slice) and blood (same slice) on the precontrast images and transposed to the post-contrast images. All analysis was performed blinded. We quantified ECM expansion with ECV defined as (8) :
LABORATORY HCT VARIABILITY. Whole blood for venous Hct was drawn in all subjects by venipuncture and analyzed as routine clinical samples using a Sysmex XE-2100 hematology analyzer (Sysmex, Kobe, Japan) (32) . Repeat sampling variability was tested in 44 patients who underwent 2 samples a median of 4 h apart.
SYNTHETIC HCT DERIVATION. The longitudinal relaxivity (R1 ¼ 1/T1) of blood has a linear relationship with blood Hct, and is determined by the relaxivity of the water fractions of plasma (R1 P ) and the erythrocyte cytoplasm (R1 RBC ) (19): Values are median (interquartile range) or n (%).
CMR ¼ cardiac magnetic resonance; LGE ¼ late gadolinium enhancement.
Treibel et al. Figure 1) . The regression equations were:
where Hct is hematocrit (0 to 1) and R1 blood ¼ (1/T1 blood ) in milliseconds.
Using these curve-fits in the validation cohort, synthetic and conventional ECV were highly correlated (R 2 ¼ 0.97; p < 0.001, both mapping techniques) with a 2.8% SD of differences and minimal bias on Bland-Altman analysis for fibrosis quantification and a slightly higher SD in difference of 5% in extracellular expansion due to amyloidosis (Figure 2 ).
Synthetic and conventional ECV correlated equally
with clinical markers of disease severity (Online Table S1 ). OUTCOME COHORT. Baseline characteristics are presented in Table 3 . The U.K. derivation resulted in a 2% bias in synthetic ECV; therefore, a local synthetic Using these curve-fits in the validation cohort, synthetic and conventional extracellular volume fraction (ECV) were highly correlated (R 2 ¼ 0.97; p < 0.001, both mapping techniques) with a 2.8% SD of differences and minimal bias on Bland-Altman analysis for fibrosis quantification and a slightly higher SD in difference of 5% in extracellular expansion due to amyloidosis.
workflow, providing automated immediate point-ofcare results.
The technique arose out of need and the observation that pre-contrast blood T1 is considerably determined by hematocrit (pre-contrast blood T1 increases with anemia). Indeed, the linear relationship between
Hct and R1 blood (1/T1 blood ) has been abundantly described (7, (14) (15) (16) (17) (18) (19) (20) , and therefore, R1 blood was used for curve fitting. Beyond mathematical derivation, we describe 1/T1 blood because it is more intuitive for the CMR clinicians and easier to sell to the CMR community. This is analogous to the T2* field that uses T2* rather than the R2*. Although the correlation of peripheral Hct and ventricular cavity pre-contrast R1 blood is only moderate (other influences are discussed in the following text), synthetic ECV performance is good, which we believe is in part due to considerable error in standard laboratory Hct when taken as a routine clinical test, and also because the ECV has other dependencies that make it robust (6, 9, 10, 36) . It may be that an overlooked weakness has been the variability of Hct measurement (37) .
Here, the correlation of 2 Hct samples on the same day to a clinical service (located in a different building so with potential settling and re-suspension of red cells during transport) was only a R 2 of 0.86-potentially a greater source of inaccuracy than the differences contested between T1 mapping approaches (30, 38) .
ECV is gaining recognition as a potentially key biomarker of ECM expansion and has been called volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J Am Heart Assoc 2015;4:e002613. 
